These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 16755185

  • 1. Biology of ductal carcinoma in situ classification based on biologic potential.
    Tsikitis VL, Chung MA.
    Am J Clin Oncol; 2006 Jun; 29(3):305-10. PubMed ID: 16755185
    [Abstract] [Full Text] [Related]

  • 2. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM.
    Breast Cancer Res; 2008 Jun; 10(5):R87. PubMed ID: 18928525
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Actual management of ductal carcinoma in situ of the breast.
    Maass N, Alkasi O, Bauer M, Jonat W, Souchon R, Meinhold-Heerlein I.
    Arch Gynecol Obstet; 2009 Nov; 280(5):699-705. PubMed ID: 19259692
    [Abstract] [Full Text] [Related]

  • 5. The natural history of ductal carcinoma in situ of the breast: a review.
    Erbas B, Provenzano E, Armes J, Gertig D.
    Breast Cancer Res Treat; 2006 May; 97(2):135-44. PubMed ID: 16319971
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biological variables and prognosis of DCIS.
    van de Vijver MJ.
    Breast; 2005 Dec; 14(6):509-19. PubMed ID: 16246564
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
    Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 1):467-74. PubMed ID: 17255267
    [Abstract] [Full Text] [Related]

  • 11. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
    Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu SI.
    Ann Clin Lab Sci; 2006 Jan 15; 36(1):16-22. PubMed ID: 16501232
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Progression of heterogeneous breast tumors.
    Subramanian B, Axelrod DE.
    J Theor Biol; 2001 May 07; 210(1):107-19. PubMed ID: 11343435
    [Abstract] [Full Text] [Related]

  • 15. [Does molecular biology play any role in ductal carcinoma in situ?].
    Sakr RA.
    Gynecol Obstet Fertil; 2013 Jan 07; 41(1):45-53. PubMed ID: 23286959
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O.
    Pathol Res Pract; 2006 Jan 07; 202(8):569-76. PubMed ID: 16828238
    [Abstract] [Full Text] [Related]

  • 18. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: analysis of loss of heterozygosity.
    Smeds J, Wärnberg F, Norberg T, Nordgren H, Holmberg L, Bergh J.
    Acta Oncol; 2005 Jan 07; 44(1):41-9. PubMed ID: 15848905
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
    Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ.
    Br J Cancer; 2006 Jan 30; 94(2):253-8. PubMed ID: 16421596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.